Fresenius Medical Care AG & Co. (FMS) Expected to Announce Earnings of $0.51 Per Share

Equities research analysts expect Fresenius Medical Care AG & Co. (NYSE:FMS) to post earnings per share of $0.51 for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Fresenius Medical Care AG & Co.’s earnings. The lowest EPS estimate is $0.49 and the highest is $0.52. Fresenius Medical Care AG & Co. posted earnings per share of $0.48 in the same quarter last year, which suggests a positive year-over-year growth rate of 6.3%. The business is scheduled to announce its next quarterly earnings results on Monday, August 7th.

On average, analysts expect that Fresenius Medical Care AG & Co. will report full-year earnings of $2.21 per share for the current fiscal year, with EPS estimates ranging from $2.11 to $2.32. For the next year, analysts expect that the company will post earnings of $2.37 per share, with EPS estimates ranging from $2.24 to $2.44. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Fresenius Medical Care AG & Co..

Fresenius Medical Care AG & Co. (NYSE:FMS) last posted its quarterly earnings results on Wednesday, May 3rd. The company reported $0.53 EPS for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.09. Fresenius Medical Care AG & Co. had a return on equity of 10.56% and a net margin of 6.67%. The firm had revenue of $4.55 billion during the quarter, compared to analyst estimates of $4.69 billion. During the same period last year, the company earned $0.75 earnings per share.

Several research analysts recently weighed in on the stock. Royal Bank of Canada reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a report on Wednesday, May 3rd. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Fresenius Medical Care AG & Co. in a report on Sunday, March 12th. Zacks Investment Research downgraded shares of Fresenius Medical Care AG & Co. from a “buy” rating to a “hold” rating in a report on Friday. Societe Generale downgraded shares of Fresenius Medical Care AG & Co. from a “buy” rating to a “hold” rating in a report on Friday, February 24th. Finally, DZ Bank AG reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a report on Monday, January 9th. Six research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $47.00.

Shares of Fresenius Medical Care AG & Co. (NYSE:FMS) opened at 46.34 on Tuesday. The company has a 50 day moving average price of $42.95 and a 200-day moving average price of $41.40. The stock has a market cap of $28.38 billion, a P/E ratio of 20.70 and a beta of 0.53. Fresenius Medical Care AG & Co. has a 12 month low of $38.05 and a 12 month high of $47.52.

The company also recently announced an annual dividend, which will be paid on Friday, May 26th. Investors of record on Monday, May 15th will be issued a $0.5137 dividend. This represents a yield of 1.17%. The ex-dividend date of this dividend is Thursday, May 11th. Fresenius Medical Care AG & Co.’s dividend payout ratio is currently 16.23%.

ILLEGAL ACTIVITY WARNING: This report was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright legislation. The legal version of this report can be viewed at https://sportsperspectives.com/2017/05/19/fresenius-medical-care-ag-co-fms-expected-to-announce-earnings-of-0-51-per-share-updated.html.

Hedge funds and other institutional investors have recently modified their holdings of the company. UBS Asset Management Americas Inc. purchased a new position in shares of Fresenius Medical Care AG & Co. during the fourth quarter valued at $1,133,000. Quadrant Capital Group LLC increased its position in Fresenius Medical Care AG & Co. by 12.7% in the first quarter. Quadrant Capital Group LLC now owns 3,736 shares of the company’s stock valued at $149,000 after buying an additional 420 shares during the period. Greenleaf Trust bought a new position in Fresenius Medical Care AG & Co. during the first quarter valued at approximately $205,000. Trexquant Investment LP bought a new position in Fresenius Medical Care AG & Co. during the fourth quarter valued at approximately $215,000. Finally, BOKF NA bought a new position in Fresenius Medical Care AG & Co. during the third quarter valued at approximately $235,000. 2.52% of the stock is owned by institutional investors.

Fresenius Medical Care AG & Co. Company Profile

Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.

5 Day Chart for NYSE:FMS

Get a free copy of the Zacks research report on Fresenius Medical Care AG & Co. (FMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply